autologous anti-h3.3k27m tcr-expressing t-cells
Cell therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2023 (NCT05478837)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Histone-lysine N-methyltransferase Su(var)3-9Immunity, passive
SU(VAR)3-9 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05478837 | Phase 1 | Feb 1, 2023 | The Parker Institute, University of California, San Francisco, V Foundation |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| The Parker Institute | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2023 |
| V Foundation | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1